Merck (MRK)
$92.82
0.33 (0.36%)
MRK Stock Quote Delayed 30 Minutes
Top 10 Dow Dividend Stocks
Whether you're looking for a low-risk way to ride the rally or just want a safe place to park your cash, look no further than these blue-chip dividend champs.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$92.25
Market Cap
233.03B
PE Ratio
13.78
EPS
6.7363
Volume (Avg. Vol.)
12.30M
Day's Range
$91.78 - $93.21
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.36%)
MRK Stock Predictions, Articles, and Merck News
How to Pick the Best High-Yield Stocks in Big Pharma
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Pfizer Tops Q2 Earnings Estimates
Pfizer posted second-quarter earnings that topped Wall Street estimates even as revenue declined compared to last year.
This New ETF Revolves Around Rotation
The lone new ETF last week, U.S. Equity Rotation Strategy, will shift its holdings among sectors according to the fund managers' view of the markets.
Should I Buy Merck? 3 Pros, 3 Cons
Pharma is a tough game, but thanks to its simultaneous continued R&D spending and cost-cutting, Merck has what it takes to win. Or does it?
6 Pharmaceutical Stocks to Buy Now
The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
For Older Investors, Dividends Trump Bonds
It may not be a surprise that the older demographic tends to be drawn towards dividend stocks, but some other details about dividend investors may surprise you.
Top 10 Dow Dividend Stocks
Looking for the biggest brands with the biggest yields? These 10 blue-chips throw off the best dividends across the entire Dow Jones.
Divided, This Rally Cannot Stand!
The fact that Thursday's rally was restricted to just several sectors following a breakout means a slight correction could be due. Watch for new entry points.
Chasing Yield: Love Dividends, But Diversify
Dividends are popular picks these days, but investors need to be careful. Don't pull all your eggs into one basket just because you see a high yield.
The New Nifty Fifty
Long-term investors may find opportunities in this group of largely household names -- with steady earnings and often above-average dividends.
Where Are the Women Board Members?
Big U.S. companies lag badly when it comes to getting females on the board, and they're missing a chance to do what's right -- for the bottom line.
Merck Could Have a Home Run in Sight
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.
Look What’s Up When the Market’s Are Down
Despite a down day Thursday consumer, pharmaceutical and utility ETF's did very well and investors may want to look at the sectors for investment
Investors Bag the Groceries: Thursday’s IP Market Recap
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.
4 ETFs to Guard Against Market Volatility
Worried about the market's current uncertainty? A good defensive play right now is low-risk, low-beta ETFs. Here are four of the best.
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.
Dividends Do Matter in Dud Stocks
For those investors watching their investments lose ground, the dividends really do matter. But ... stock appreciation should make your checklist, too.
What’s the Real Impact of Generic Drugs?
The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.
